Project Grant R01AG100181
- The National Institute on Aging awarded the University of Florida $5.551 million on July 1, 2026, under the Aging Research program (CFDA 93.866) to identify neural signatures that distinguish early Alzheimer's disease from normal aging. The recipient will record electrical activity from ten brain regions across the lifespan in human tauopathy mouse models (HTAU mice) and wild-type controls (C57BL/6J), computing new electrical oscillatory features called electome factors to distinguish between...
- The National Institute on Aging awarded the University of Florida $788,481 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop clinical diagnostic tools for chronic traumatic encephalopathy (CTE) during life, distinguishing CTE from Alzheimer's disease and related dementias. The research will apply automated imaging differentiation of dementia (AIDD), a novel disease classification method, to brain imaging data. Blood-based biomarkers (NulisaSeq) will complement...
- The National Institute on Aging awarded $191,832 to North Florida Foundation For Research And Education, Inc. on August 15, 2026, under the Aging Research program (CFDA 93.866) to support a K23 career development grant focused on brain aging and Alzheimer's disease risk. The award funds research investigating the relationship between cognition and the autonomic regulatory system in older adults at varying risk for Alzheimer's disease and related dementias. The principal investigator will...
- The National Institute on Aging awarded $526,607 to Wake Forest University on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop computational imaging frameworks that integrate neuroimaging with multi-omics data to identify Alzheimer's disease subtypes and model neurodegenerative progression with calibrated uncertainty. The project, titled "Neuroimaging Multi-Omics Fingerprints for Subtyping and Uncertainty-Aware Prediction of Alzheimer's Disease," will...
- The National Institute on Aging awarded the University of Florida $182,570 on July 1, 2026, under the Aging Research program (CFDA 93.866) to conduct a prospective cohort study validating diffuse optical tomography (DOT) as a portable neuroimaging biomarker for mapping brain function in delirium and post-delirium Alzheimer's disease and related dementias. The award supports research examining whether DOT can identify impaired cerebral oxygenation and functional dysconnectivity in the...
- The National Institute on Aging awarded Trustees of Indiana University (doing business as Indiana University Indianapolis) $791,039 on September 1, 2026, under the Aging Research program (CFDA 93.866) to develop computational methods enabling patient-centered prognostic profiling for Alzheimer's disease and related dementias that accounts for individual cognitive resilience in response to neuropathological changes. The work will model each patient's distinct connectome architecture and cognitive...
- The National Institute on Aging awarded the University of South Florida $3,331,541 on September 22, 2025, under the Aging Research program (CFDA 93.866) to conduct transcriptome-wide mapping of brain N6-methyladenosine (m6A) methylome in Alzheimer's disease. The award runs through May 31, 2030, with place of performance in Tampa, Florida. The research will create the first high-resolution reference map of brain m6A methylome in older adults using novel base-resolution quantitative m6A...
- The National Institute on Aging awarded the University of Florida $439,739 on June 1, 2026, under the Aging Research program (CFDA 93.866) to investigate biobehavioral signatures of repetitive head impacts at the intersection of aging and Alzheimer's disease. The award funds a longitudinal multi-site study examining fluid biomarkers, neuroimaging, and cognition in aging adults with and without prior repetitive head impacts (RHI). The research addresses how RHI—exposure from contact sports,...
- The National Institute on Aging awarded the University of California, San Diego $150,512 on August 2, 2026, under the Aging Research program (CFDA 93.866) to develop and validate a novel diffusion MRI neuroimaging biomarker for early detection of Alzheimer's disease. The project focuses on microstructural changes in gray matter mean diffusivity (GMD) that may precede macrostructural atrophy visible on conventional MRI. Current AD detection relies primarily on macrostructural metrics such as...
- The National Institutes of Health's National Institute on Aging awarded $256,331.40 under the Aging Research program (CFDA 93.866) to The Trustees of the University of Pennsylvania from February to October 2021. The project aims to develop novel machine learning algorithms and biomedical software to more accurately quantify brain aging and predict the onset of neurodegenerative diseases such as Alzheimer's. Specifically, the funding will support refining predictive models of the...
The National Institute on Aging awarded the University of Florida $597,264 on August 15, 2026, under the Aging Research program (CFDA 93.866) to develop and deploy the Automated Neurodegeneration Index (ANDI), a machine learning software tool that quantifies neurodegeneration severity in at-risk populations for Lewy body disease. ANDI uses routine 3 Tesla diffusion MRI scans and an automated free-water algorithm to generate a standardized, individual-based neurodegeneration index scaled from 0 to 1, with higher scores indicating greater severity. The project deploys ANDI across two cohorts at significantly elevated risk for Parkinsonism and dementia: early-stage REM sleep behavior disorder (RBD), which progresses to overt synucleinopathy in 90 percent of patients, and inflammatory bowel disease (IBD), an autoimmune disorder implicated in gut-brain axis-mediated pathogenic spread of alpha-synuclein. The longitudinal study includes baseline assessment and 24-month follow-up to establish ANDI as a sensitive, standardized imaging marker for early neurodegeneration and disease progression tracking. Work is performed at the University of Florida in Gainesville, Florida. The period of performance runs from August 15, 2026, through April 30, 2031. The award is structured as a project grant, the standard assistance type for NIH investigator-initiated research.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $597.3k | 8/12/26 |